Skip to main content
BLUDOTCinactive

IMMUCOR INC

·Commercial
Nephrology

BLUD evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for BLUD—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

4.9/10

BioSniper Score

Based on 4 of 6 signals

Market Cap

—

Cash Runway

18.7 mo

Lead Asset

mia fora ngs (Approved)

Next Catalyst

—

Financial data as of Feb 28, 2017.

Tracking 2 pipeline candidates for IMMUCOR INC.

Run IMMUCOR INC through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available IMMUCOR INC facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 4 of 6 signals · derived from public data

Cash Runway5.2

18.7 months

Financial Health0.0

D/E 4.46

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Run my thesis on this company

Pipeline

Run my thesis on this company

Financials

Run my thesis on this company

Frequently asked questions

What is IMMUCOR INC's lead drug candidate?

IMMUCOR INC's most advanced tracked candidate is mia fora ngs (Approved) for High resolution typing for transplants.

What therapeutic areas does IMMUCOR INC focus on?

IMMUCOR INC develops therapies across Nephrology.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.